Search Results 161-170 of 17517 for Bronchodilators

1. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   Intermittent use of bronchodilators or local steroid injections;; Non-immunosuppressive maintenance treatments in the setting of clinically asymptomatic ...

2. Pulmonary Medicine - Doctors - Mayo Clinic

   Pulmonologist. Phoenix, AZ. Areas of focus: Bronchoscopy, Bronchoalveolar lavage, Pulmonary function test, Thoracentesis, Spirometry with bronchodilator, Asthma ...

3. Movement disorders - Doctors and departments - Mayo Clinic

   Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

4. Movement disorders - Doctors and departments - Mayo Clinic

   Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

5. Phase ll Study of Pirfenidone in Patients With RAILD - Mayo Clinic

   Post-bronchodilator FEV1/FVC < 0.65 at Screening. Presence of pleural effusion occupying more than 20% of the hemithorax on Screening HRCT. Clinical ...

6. A Study To Evaluate Pemetrexed And Pembrolizumab To Treat Recurrent And/or Metastatic Salivary Gland Malignancies - Mayo Clinic

   Intermittent use of bronchodilators or inhaled steroids;. Daily steroids at dose of ≤ 10mg of prednisone (or equivalent);. Local steroid injections;. Stable ...

7. A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis - Mayo Clinic

   Post bronchodilator forced expiratory volume in 1 second (FEV1)/FVC ratio < 0.7 at screening; Positive bronchodilator response, evidenced by an increase of > ...

8. A Study Of The Gala Airway Treatment System For The Treatment Of Chronic Bronchitis In The United States - Mayo Clinic

   Subject has preprocedure post-bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within three months of enrollment.

9. Efficacy And Safety Of Nintedanib In Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - Mayo Clinic

   Primary obstructive airway physiology (pre-bronchodilator FEV1/FVC < 0.7 at Visit 1). In the opinion of the Investigator, other clinically significant ...

10. Pulmonary Medicine - Doctors - Mayo Clinic

    Pulmonologist. Phoenix, AZ. Areas of focus: Bronchoscopy, Pulmonary function test, Thoracentesis, Bronchoalveolar lavage, Spirometry with bronchodilator, Asthma ...